⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336146 | 0.67 | — | — | |
| SCHEMBL5732700 | 0.67 | — | — | |
| SCHEMBL2044148 | 0.67 | — | — | |
| SCHEMBL3145175 | 0.67 | — | — | |
| SCHEMBL9296811 | 0.65 | — | — | |
| SCHEMBL1621071 | 0.62 | ALDH1A1 (0.32) | — | |
| SCHEMBL11245717 | 0.62 | — | — | |
| SCHEMBL1829634 | 0.62 | — | — | |
| SCHEMBL3136394 | 0.62 | — | — | |
| SCHEMBL6757101 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385980-A1 | INDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2024-06-19 | — | — | EP | claimed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | claimed |
| CN-113521079-A | Use of IRAK4 inhibitors for the treatment of ALI/ARDS | 上海领泰生物医药科技有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-109641906-B | Heteroaryl substituted aminopyridine compounds | 百时美施贵宝公司 | 2021-10-01 | — | — | CN | claimed |
| WO-2021011868-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | claimed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | claimed |
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | claimed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | claimed |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | claimed |
| EP-3475270-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | claimed |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-27 | — | — | US | claimed |
| WO-2016210036-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-29 | — | — | WO | claimed |
| EP-2917206-B1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | claimed |
| EP-3089973-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2016-11-09 | — | — | EP | claimed |
| US-9169252-B2 | Heteroaryl substituted nicotinamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | claimed |
| US-20150284382-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | claimed |
| EP-2917206-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | Bristol-Myers Squibb Company (US) | 2015-09-16 | — | — | EP | claimed |
| WO-2015103453-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | claimed |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | claimed |
| WO-2014074675-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | claimed |